Regeneron Starts Phase 3 Trial of Covid Antibody Drug - COVID-19 Clinical Trial
Breaking News | COVID-19

Regeneron Starts Phase 3 Trial of Covid Antibody Drug

An antibody cocktail is now beginning late-stage clinical trials to evaluate the drug’s ability to prevent and treat coronavirus infection.The biotechnology company Regeneron announced the late-stage clinical trials of REGN-COV2, its investigational double antibody cocktail for the treatment and prevention of Covid-19, in a news release on Monday.Specifically the release noted that a Phase 3 trial of the drug will assess its ability to prevent coronavirus infection among uninfected people who have had close contact to an infected person, such as a patient’s housemate. The Phase 3 prevention trial is happening at around 100 sites and expected to include 2,000 patients across the United States, according to Regeneron.

Sanofi, Regeneron Shut Down Kevzara Trial in COVID-19 After Finding No Benefit For Ventilated Patients

In the early days of the COVID-19 pandemic, Sanofi and Regeneron launched an ambitious plan to try out rheumatoid arthritis med Kevzara in desperately ill patients. But after early warning signs, a phase 3 flop has forced the drugmakers to can their U.S. trial.

Sanofi and Regeneron have stopped their stateside study of Kevzara in mechanically ventilated COVID-19 patients after the drug failed to prevent deaths or get patients off ventilation, among other key endpoints, the drugmakers said Thursday.

Kevzara, added to standard-of-care therapy, not only failed to better patients’ condition after 22 days, but the drug’s “minor positive trends” in ventilated patients were also offset by poor results in a partially enrolled subgroup that had not been ventilated at the start of treatment, the companies said.

Share this:

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.